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ImmunotherapyAbstract Pancreatic cancer is an aggressive type of malignancy. Generally, its promotion and pro-
gression are due to the disturbance in some cellular and molecular mechanisms, particularly dereg-
ulation of programmed cell death or apoptosis. Certainly, loss of counterbalance between
generation and cell death will lead to the tumoural mass development in various tissues, such as
pancreas.
From earlier decades, a variety of treatments as chemotherapy, radiation and surgery have been
employed in order to pancreatic cancer remedial purposes, which are associated with inﬁrm medical
outcome. Therefore, with regard to the anti-cancerous and pro-apoptotic properties of the cytokine
interleukin-25 (IL-25), the authors intend to anticipate a new therapeutic strategy. IL-25 – known as
IL-17E – is one of the major factors responsible for death receptor-mediated pathway. Broadly, its
receptor is located on multifarious cells such as pancreatic cancerous cells. We proposed to select
four groups of C57BL/6 mice, for IL-25 gene inoculation, via mesenchymal stem cells as a vector,
in order to increase exposure of cancerous cells to IL-25. IL-25 could activate apoptotic mediators
including tumour necrosis factor receptor associated factor (TRAF6), Fas-Associated protein with
Death Domain (FADD) and caspases consequently. Probably this method will be efﬁcient in pan-
creatic malignancy treatment, via inducing apoptosis in pancreatic tumoural cells.
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Worldwide, pancreatic cancer is the eighth and ninth leading
cause of death in males and females, respectively [1], and esti-
mated incidence of pancreatic cancer is 0.39% in females and
0.56% in males in the Iranian population [2]. Approximately
95% of exocrine pancreatic cancer cases are ductal [3]. Fur-
thermore, just 5% of patients can survive 1–5 years after treat-
ment [4]; therefore it is noted as one of the most life-
threatening cancers. Cancer of the pancreas often develops
without early symptoms, although, generally, pain, anorexia,
early satiety, sleep problems and weight loss are present in ad-
vanced stages of malignancy [5].
As previously mentioned, pancreatic cancer frequently ini-
tiates in the ducts that transmit digestive enzymes to the small
intestine, typically recognised as ductal adenocarcinoma
(DAC). Tumour development and progress of pancreatic duc-
tal adenocarcinoma (PDAC) as well as resistance to most
oncology therapies involve the absence of a reaction to apop-
totic stimuli [3].
Activation of the Kirsten rat sarcoma viral oncogene
homologue (KRAS) has been indicated in more than 90% of
pancreatic cancers and KRAS mutation represents one of
the earliest genetic alterations in pancreatic carcinogenesis
[6]. In addition, mutation or deregulating of several genes such
as p53, p16, DPC4/smad4, SFN, miR-15a and FN1 genes in pa-
tients with pancreatic cancer have been shown [7–10], although
the use of these genes as biomarkers for prognosis and thera-
peutic purposes is still little known and deserves more study
[11]. In addition, the major role of p53 and p16 genes in apop-
tosis control is well established and dysfunction of these genes
deﬁnitely will lead to a malignant lump in the pancreas [12,13].
On the other hand, it is proved that disruption of apoptosis is
one of the major characteristics of pancreatic tumoural cells
and other types of cancer [14,15].
Likewise, inﬂammatory processes, cytokines and oxidative
stress play an important role in this malignancy and increaseFigure 1 This schematic shows the expression of IL25R on pancreat
TRAF6 and FADD.disease risk [16,17]. Research has illustrated reduction in cellu-
lar antioxidant level in chronic pancreatitis and pancreatic can-
cer [18].
Poor response to common treatments such as chemother-
apy, radiotherapy and surgery with dismal prognosis made
us to evaluate a new treatment strategy for pancreatic cancer.
In fact, it is necessary to develop an impressive treatment with
the minimum side effects alongside the highest efﬁciency
[19,20]. Recently, Furuta et al. discovered that interleukin-25
(IL-25) can be used as a cytokine against breast tumoural cells,
via its receptors at these cell surfaces. IL-25 is a member of the
IL-17 family of pro-inﬂammatory cytokines and some of its
biologic effects have been discovered recently [21]. The IL-25
locus is on chromosome 14, (14q11-12) [22], and has been
shown to play a critical role in the initiation and propagation
of the Th2 immune response [23–25], Research about IL-17E
(IL-25) has demonstrated that its function is meaningfully dif-
ferent from the other family members and its overexpression is
associated with type 2 responses by major histocompatibility
complex (MHC) class II [26], alongside elevated IL-4, IL-5
and IL-13 [27,28].
The IL-25 receptor is similar to the receptors of other mem-
bers of the IL-17 family [29,30], such as IL-17RA and IL-17RB
[30–33], and is located on the cells of pancreas, prostate
[29,30,32], kidney [32], lung [34] and liver [29]. With respect
to recent investigations, IL-25 has an apoptotic effect in breast
tumoural cells and could eliminate tumoural cells without any
effect/impact on the intact cells. IL-25 operates very speciﬁ-
cally and just eliminates cancerous cells with the least compli-
cations. Due to this fact that, these cells express abundant
amounts of IL-25 receptors, but the blood level of IL-25 is re-
duced for unknown reasons [21].
IL-25 signalling pathway
It has been proved that TRAF6 family proteins play a crucial
part, in various cell signalling pathways. For example, TRAF6ic tumoral cells that induces apoptosis via recruiting of TRADD,
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immunity, bone metabolism and cell apoptosis [35]. Moreover,
tumour necrosis factor receptor associated death domain
(TRADD can activate an apoptosis pathway [36,37]. TRADD
connects to the death domain of Fas-Associated protein with
Death Domain (FADD), and then caspase-8 pathway will be
initiated [38] (Fig. 1).
Hypothesis
Although pancreatic cancer is one of the most aggressive types
of cancers, its treatment has not succeeded, due to the higher
resistance to usual treatment such as surgery, radiation and
chemotherapy. Therefore, the authors, taking advantage of
animal modelling and immune gene therapy, suggest a novel
strategy in pancreatic cancer treatment.
As IL-25 binding to its receptor leads to apoptosis of can-
cerous cells, it can also be used to treat pancreatic cancer [39],
because one of the main causes of pancreatic cancer is resis-
tance to apoptosis [40].
Considering the fact that, pancreatic tumoural cells pro-
duce the IL-25 receptor, but do not express IL-25 [41], the
injection of IL-25 gene into the animal model as gene therapy,
via mesenchymal stem cells (MSCs), can increase the malig-
nant cells’ exposure with an optimal IL-25, and lead to apop-
tosis of pancreatic tumoural cells.
Evaluation of hypothesis
(1) A total of 40 female C57BL/6 mice (8–10 weeks old) are
prepared [42]. The ﬁrst group (n= 10) contains control
animals, which do not receive any injection. The remain-
ing mice are divided into three categories of 10 animals
per group, including the following:(a) Ten mice are selected for Panc02 cell line inocula-
tion subcutaneous (s.c.) in the right hind ﬂank [-
43], in order to induce a tumour without IL-25
transfection.
(b) The next group encompasses mice that are manip-
ulated with IL-25 gene via bone marrow-derived
cells (MSCs).
(c) Finally, the last group contains receivers of MSCs
without the IL-25 gene.(2) The Panc02 (Panc02 is a murine ductal pancreas adeno-
carcinoma cell line that was established in 1984 in female
C57BL/6 mice) cell line is cultured in Roswell Park
Memorial Institute medium (RPMI) with 10% foetal
bovine serum and 2 mM L-glutamine, 100 U ml1 peni-
cillin and 100 lg ml1 streptomycin and incubated at
37 C with 5% CO2 in a humidiﬁed atmosphere [44].
(3) Thirty mice are anaesthetised using a mixture of keta-
mine/xylazine, the control mice do not receive injection.
A total of 5 · 105 Panc02 cells in 50 ll phosphate buf-
fered saline (PBS) are inoculated in the ﬂank of mice
to induce pancreatic cancer [43]. The mice are euthan-
ised 14 days after inoculation.
(4) Comparison of tumour size and pathologic aspects of
tumour cells with immunohistochemical and haematox-
ylin and eosin staining methods in both control and micetreated with IL-25 in terms of its impact on the growth
cease of cancerous cells and reduction in tumour size
[22,45].
(5) Isolation of MSCs from 6–8 week-old C57BL/6 mice.
C57BL/6 mice are killed by cervical dislocation. Bone
marrow is collected from the tibia and the femur of
mice. A total of 70 · 106 bone marrow cells from one
donor are obtained [46,47]. Then, 25 · 106 cells are pre-
pared [47] and suspended in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 15% foetal bovine serum
(FBS), penicillin and streptomycin. After 24 h, cells are
washed and non-adherent cells, which mostly are hae-
matopoietic stem cells, removed. Adherent cells are cul-
tured in complete medium for 1 week until they covered
80–90% of the bottom of the culture bottle. MSCs, from
passage 4, are used in the subsequent experiments.
Mature MSCs are determined by their ability to differ-
entiate into adipocytes and osteocytes. Further proper-
ties are based on the expression of surface markers
such as CD34, CD44, Stem Cell Antigen-1 (Sca-1) and
Vimentin Cell Adhesion Molecule-1 (Vcam-1) [46–48].
(6) Use of MSCs of C57BL/6 mice as a vector for IL-25
gene transfection into 10 mice by the lipofection method.
(This transplantation is distinguished as a syngeneic sys-
tem: A transplantation in which donor and receiver are
genetically identical.)
(7) To measure levels of IL-25 in blood, in the four groups
via enzyme-linked immunosorbent assay (ELISA), the
apoptotic tumour cells in the tumour tissues are charac-
terised by the terminal deoxynucleotidyl transferase-
mediated deoxyuridine use of tri-phosphate nick-end
labelling (TUNEL) test to assay DNA fragmentation,
as a marker of apoptosis [49].
Conclusion and discussion
In this hypothesis, with regard to the signiﬁcance of pancreatic
cancer, authors have attempted to propose an efﬁcient, partic-
ular and affordable treatment with the least complications.
The prior remedies such as antioxidant therapy could not have
an effect on chronic pancreatitis which leads to pancreatic can-
cer [17]. As disturbance in apoptosis has a major role in pan-
creatic cancer promotion, treatment of this malignancy could
be performed using apoptosis induction [50].
IL-25, via binding to its receptor, leads to activation of cell
death pathways in tumoural cells, because IL-25R strongly
interacted with FADD and TRADD (IL-25R contains a death
domain (DD)-like segment).
These results indicate that IL-25 binding to its receptor increases
the stability of the IL-25R-associated complex, which includes
FADD and TRADD. This complex then triggers the activation of
caspases 8 and 3 sequentially for apoptotic signalling [21].
As a result, we could utilise this pathway, in induction of
apoptosis in cells that posses receptors of IL-25 on their sur-
face, including pancreatic cancer cells.
In this hypothesis, we suggest pancreatic cancer treatment
with use of MSCs, as a vector to transfer the IL-25 gene into
mice. As indicated, MSCs possess certain features such as hom-
ing capabilities in a wide range of pathological conditions, easy
expansion in culture andmulti-lineage potential. They also seem
78 Z. Piri et al.to be relatively immunoprivileged due to their expression of
MHCI, but lack MHCII and the co-stimulatory molecules
CD80, CD86 and CD40. These characters make MSCs suitable
as a vector to transport anti-cancerous drugs [51].
As a whole, the IL-25/IL-25R signalling pathway may act
as a new therapeutic object for pancreatic cancer. The cytokine
IL-25 wisely attacks only the cancer cells but not the normal
cells. It seems that IL-25 can operate as a stimulator cytokine,
in a mouse model of pancreatic cancer cell death.
We could conclude that use of IL-25 immunogene therapy
probably operates as a novel treatment in a mouse model, and
in the next step could lead to design a new clinical trial about
this strategy and its outcome in humans.Overview Box
First Question: What do we already know about the
subject?
From 1998, the pancreatic cancer rate has been
increasing by 0.8% in men and by 1.0% in women
each year. Nowadays, there is not any efﬁcient tech-
nique for prognosis of pancreatic cancer and the com-
mon treatments are not beneﬁcial, because pancreatic
cancer is usually detected after it has spread beyond
the pancreas.
Second Question: What does your proposed theory
add to the current knowledge available, and what ben-
eﬁts does it have?
According to Furuta’s discovery, which revealed
that malignant mammary epithelial cells express
plenty of IL-25 receptors which respond to IL-25
secreted by other non-malignant mammary epithe-
lial cells (MECs), which induces caspase-mediated
apoptosis in cultured breast cancer cells with IL-
25R, but had no detrimental effect on non-malig-
nant cells, the authors proposed that IL-25 could
be effective and advantageous in apoptosis of pan-
creatic tumoural cells.
Third question: Among numerous available studies,
what special further study is proposed for testing the
idea?
To test this hypothesis, initially pancreatic tumoural
cells are induced in a mouse model via MSCs. Then,
investigator could assess how the cells will respond
to the treatment with IL-25 by means the methods
of measurement of pathologic properties and bio-
markers in blood levels.
After proving the response to treatment, in a mouse
model, the injection of IL-25 gene into patient could
be performed.Conﬂict of interest
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